http://rdf.ncbi.nlm.nih.gov/pubchem/reference/34689448

Outgoing Links

Predicate Object
contentType Journal Article
endingPage 523
issn 2577-171X
issueIdentifier 6
pageRange 521-523
publicationName IJU Case Reports
startingPage 521
bibliographicCitation Fukunaga H, Sumii K, Kawamura S, Okuno M, Taguchi I, Kawabata G. A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab. IJU Case Rep. 2022 Nov;5(6):521–3. PMID: 36341187; PMCID: PMC9626353.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_58070998954067d3602dc6683061a8ae
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a6adcf5d053e480febd1d6a7d96514bc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-6111-0305
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fb9a124d10c797d8610a3641a7c91654
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7fe936ba5424c40ab5c2d931223bcb18
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0e79a1f71d24bfe80de84f12dc81febb
date 2022-09-24^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/36341187
https://pubmed.ncbi.nlm.nih.gov/PMC9626353
https://doi.org/10.1002/iju5.12532
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/49421
https://portal.issn.org/resource/ISSN/2577-171X
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7384
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7518
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5755
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8366
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9556
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11347
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8756

Showing number of triples: 1 to 32 of 32.